Integra LifeSciences Holdings Corporation (FRA:IL3)
Germany · Delayed Price · Currency is EUR 11.10
-0.20 (-1.77%)
At close: Dec 1, 2025
FRA:IL3 Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 1,643 | 1,611 | 1,542 | 1,558 | 1,542 | 1,372 | Upgrade | |
Revenue Growth (YoY) | 4.99% | 4.47% | -1.03% | 0.99% | 12.43% | -9.60% | Upgrade |
Cost of Revenue | 698.24 | 651.41 | 593.66 | 587.36 | 597.81 | 520.83 | Upgrade |
Gross Profit | 944.73 | 959.12 | 947.92 | 970.31 | 944.64 | 851.03 | Upgrade |
Selling, General & Admin | 681.12 | 665.53 | 592.64 | 616.32 | 637.45 | 594.53 | Upgrade |
Research & Development | 87.98 | 97.43 | 82.84 | 101.19 | 93.05 | 77.38 | Upgrade |
Amortization of Goodwill & Intangibles | 14.9 | 14.19 | 12.38 | 13.88 | 14.16 | 27.76 | Upgrade |
Operating Expenses | 784 | 777.15 | 687.86 | 731.39 | 744.66 | 699.66 | Upgrade |
Operating Income | 160.73 | 181.98 | 260.06 | 238.92 | 199.98 | 151.37 | Upgrade |
Interest Expense | -81.57 | -70.63 | -51.38 | -49.59 | -50.4 | -71.58 | Upgrade |
Interest & Investment Income | 19.01 | 20.04 | 17.2 | 11.92 | 6.74 | 9.3 | Upgrade |
Currency Exchange Gain (Loss) | -15.27 | 35.23 | -35.75 | 3.3 | - | -1.6 | Upgrade |
Other Non Operating Income (Expenses) | 13.98 | -30.98 | 38.6 | 8.71 | 19.31 | 6.03 | Upgrade |
EBT Excluding Unusual Items | 96.89 | 135.63 | 228.74 | 213.25 | 175.63 | 93.52 | Upgrade |
Merger & Restructuring Charges | -12.26 | -4.95 | -1.05 | - | - | - | Upgrade |
Impairment of Goodwill | -511.37 | - | - | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | 0.64 | 41.8 | - | Upgrade |
Asset Writedown | -4.6 | -11.7 | - | - | -2.75 | - | Upgrade |
Other Unusual Items | -113.94 | -137.22 | -146.62 | - | - | - | Upgrade |
Pretax Income | -545.27 | -18.24 | 81.07 | 213.89 | 214.68 | 93.52 | Upgrade |
Income Tax Expense | -49.94 | -11.29 | 13.33 | 33.34 | 45.6 | -40.37 | Upgrade |
Earnings From Continuing Operations | -495.34 | -6.94 | 67.74 | 180.55 | 169.08 | 133.89 | Upgrade |
Net Income | -495.34 | -6.94 | 67.74 | 180.55 | 169.08 | 133.89 | Upgrade |
Net Income to Common | -495.34 | -6.94 | 67.74 | 180.55 | 169.08 | 133.89 | Upgrade |
Net Income Growth | - | - | -62.48% | 6.79% | 26.28% | 166.71% | Upgrade |
Shares Outstanding (Basic) | 77 | 77 | 80 | 83 | 85 | 85 | Upgrade |
Shares Outstanding (Diluted) | 77 | 77 | 80 | 84 | 85 | 85 | Upgrade |
Shares Change (YoY) | -0.99% | -4.14% | -3.81% | -2.30% | 0.30% | -1.46% | Upgrade |
EPS (Basic) | -6.47 | -0.09 | 0.85 | 2.18 | 2.00 | 1.58 | Upgrade |
EPS (Diluted) | -6.47 | -0.09 | 0.84 | 2.16 | 1.98 | 1.57 | Upgrade |
EPS Growth | - | - | -61.11% | 9.09% | 26.11% | 170.69% | Upgrade |
Free Cash Flow | -4.51 | 24.96 | 73.09 | 222.13 | 264.41 | 164.94 | Upgrade |
Free Cash Flow Per Share | -0.06 | 0.32 | 0.91 | 2.66 | 3.09 | 1.94 | Upgrade |
Gross Margin | 57.50% | 59.55% | 61.49% | 62.29% | 61.24% | 62.03% | Upgrade |
Operating Margin | 9.78% | 11.30% | 16.87% | 15.34% | 12.96% | 11.03% | Upgrade |
Profit Margin | -30.15% | -0.43% | 4.39% | 11.59% | 10.96% | 9.76% | Upgrade |
Free Cash Flow Margin | -0.27% | 1.55% | 4.74% | 14.26% | 17.14% | 12.02% | Upgrade |
EBITDA | 318.82 | 322.87 | 383.57 | 357.22 | 319.82 | 267.4 | Upgrade |
EBITDA Margin | 19.41% | 20.05% | 24.88% | 22.93% | 20.73% | 19.49% | Upgrade |
D&A For EBITDA | 158.09 | 140.89 | 123.51 | 118.3 | 119.84 | 116.03 | Upgrade |
EBIT | 160.73 | 181.98 | 260.06 | 238.92 | 199.98 | 151.37 | Upgrade |
EBIT Margin | 9.78% | 11.30% | 16.87% | 15.34% | 12.96% | 11.03% | Upgrade |
Effective Tax Rate | - | - | 16.44% | 15.59% | 21.24% | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.